Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers

A global reference for human genetic variation

The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247 · see citing works

Cancer statistics, 2018

Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,632 · see citing works

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works

Analysis of protein-coding genetic variation in 60,706 humans

Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587 · see citing works

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810 · see citing works

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094 · see citing works

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · see citing works

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · see citing works

SIFT: predicting amino acid changes that affect protein function

Ng, P. C. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg509 · Cited by 6,601 · see citing works

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969 · see citing works

Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2

Adzhubei, I., Jordan, D. M., & Sunyaev, S. R. (2013) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg0720s76 · Cited by 3,705 · see citing works

Genomic analyses identify molecular subtypes of pancreatic cancer

Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · see citing works

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519 · see citing works

ClinVar: public archive of relationships among sequence variation and human phenotype

Landrum, M. J., Lee, J. M., Riley, G. R., Jang, W., Rubinstein, W. S., Church, D. M., & Maglott, D. R. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1113 · Cited by 3,516 · see citing works

Discovery and saturation analysis of cancer genes across 21 tumour types

Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096 · see citing works

Whole genomes redefine the mutational landscape of pancreatic cancer

Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · see citing works

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264 · see citing works

COSMIC: exploring the world's knowledge of somatic mutations in human cancer

Forbes, S. A., Beare, D. M., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M., Bamford, S., Cole, C. G., Ward, S. A., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku1075 · Cited by 2,261 · see citing works

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157 · see citing works

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058 · see citing works

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer

Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak‐Jones, C. L., Wolff, D. J., Younes, A., et al. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.10.002 · Cited by 2,054 · see citing works

Integrated genomic characterization of pancreatic ductal adenocarcinoma

Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019 · see citing works

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., Faluyi, O. O., O'Reilly, D. A., Cunningham, D., Wadsley, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32409-6 · Cited by 1,941 · see citing works

Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation

Kaufman, B., Shapira‐Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M. L., Balmañà, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,707 · see citing works

HGVS Recommendations for the Description of Sequence Variants: 2016 Update

den Dunnen, J. T., Dalgleish, R. W. M., Maglott, D. R., Hart, R. K., Greenblatt, M. S., McGowan‐Jordan, J., Roux, A., Smith, T. D., Antonarakis, S. E., & Taschner, P. E. M. (2016) · Human Mutation · doi:10.1002/humu.22981 · Cited by 1,662 · see citing works

Hallmarks of 'BRCAness' in sporadic cancers

Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1457 · Cited by 1,651 · see citing works

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115 · see citing works

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Tiriac, H., Belleau, P., Engle, D. D., Plenker, D., Deschênes, A., Somerville, T. D. D., Froeling, F. E. M., Burkhart, R. A., Denroche, R. E., Jang, G.-H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0349 · Cited by 1,092 · see citing works

Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

Pennington, K. P., Walsh, T., Harrell, M. I., Lee, M. K., Pennil, C. C., Rendi, M. H., Thornton, A., Norquist, B. M., Casadei, S., Nord, A. S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2287 · Cited by 1,050 · see citing works

Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development

Wu, J., Matthaei, H., Maitra, A., Molin, M. D., Wood, L., Eshleman, J., Goggins, M., Canto, M., Schulick, R., Edil, B., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002543 · Cited by 786 · see citing works

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

Javle, M. M., Lowery, M. A., Shroff, R. T., Weiss, K. H., Springfeld, C., Borad, M. J., Ramanathan, R. K., Goyal, L., Sadeghi, S., Macarulla, T. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.5009 · Cited by 695 · see citing works

Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways

Wu, J., Jiao, Y., Molin, M. D., Maitra, A., de Wilde, R. F., Wood, L. D., Eshleman, J. R., Goggins, M., Wolfgang, C. L., Canto, M. I., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118046108 · Cited by 640 · see citing works

Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial

Aung, K. L., Fischer, S. E., Denroche, R. E., Jang, G.-H., Dodd, A., Creighton, S., Southwood, B., Liang, S.-B., Chadwick, D., Zhang, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2994 · Cited by 618 · see citing works

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma

Palanisamy, N., Ateeq, B., Sundaram, S. K., Pflueger, D., Ramnarayanan, K., Shankar, S., Han, B., Cao, Q., Cao, X., Suleman, K., et al. (2010) · Nature Medicine · doi:10.1038/nm.2166 · Cited by 460 · see citing works

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers

Golan, T., Kanji, Z. S., Epelbaum, R., Devaud, N., Dagan, E., Holter, S., Aderka, D., Paluch–Shimon, S., Kaufman, B., Gershoni‐Baruch, R., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.418 · Cited by 437 · see citing works

Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia

Singhi, A. D., McGrath, K., Brand, R. E., Khalid, A., Zeh, H. J., Chennat, J. S., Fasanella, K. E., Papachristou, G. I., Slivka, A., Bartlett, D. L., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313586 · Cited by 405 · see citing works

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine

Aguirre, A. J., Nowak, J. A., Camarda, N. D., Moffitt, R. A., Ghazani, A. A., Hazar-Rethinam, M., Raghavan, S., Kim, J., Brais, L. K., Ragon, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0275 · Cited by 367 · see citing works

Targeted next‐generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas

Amato, E., Molin, M. D., Mafficini, A., Yu, J. Q., Malleo, G., Rusev, B. C., Fassan, M., Antonello, D., Sadakari, Y., Castelli, P., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4344 · Cited by 349 · see citing works

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial

Yoh, K., Seto, T., Satouchi, M., Nishio, M., Yamamoto, N., Murakami, H., Nogami, N., Matsumoto, S., Kohno, T., Tsuta, K., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30322-8 · Cited by 298 · see citing works

A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal

Sun, J., He, Y., Sanford, E. M., Montesion, M., Frampton, G. M., Vignot, S., Soria, J., Ross, J. S., Miller, V. A., Stephens, P. J., et al. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005965 · Cited by 273 · see citing works

Targeting HER2 for the Treatment of Breast Cancer

Rimawi, M. F., Schiff, R., & Osborne, C. K. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-042513-015127 · Cited by 268 · see citing works

Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial

Chantrill, L. A., Nagrial, A. M., Watson, C., Johns, A. L., Martyn-Smith, M., Simpson, S. H., Mead, S., Jones, M. D., Samra, J. S., Gill, A. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0426 · Cited by 238 · see citing works

HER2/neu-directed therapy for biliary tract cancer

Javle, M. M., Churi, C. R., Kang, H. C., Shroff, R. T., Jankú, F., Surapaneni, R., Zuo, M., Barrera, C., Al-Shamsi, H. O., Krishnan, S., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0155-z · Cited by 227 · see citing works

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms

Lowery, M. A., Wong, W., Jordan, E. J., Lee, J. W., Kemel, Y., Vijai, J., Mandelker, D., Zehir, A., Capanu, M., Salo-Mullen, E., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy024 · Cited by 224 · see citing works

Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype

Lowery, M. A., Jordan, E., Baştürk, O., Ptashkin, R. N., Zehir, A., Berger, M. F., Leach, T., Herbst, B. T., Askan, G., Maynard, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0899 · Cited by 212 · see citing works

Hypermutation In Pancreatic Cancer

Humphris, J. L., Patch, A., Nones, K., Bailey, P. J., Johns, A. L., McKay, S., Chang, D. K.-F., Miller, D. K., Pajic, M., Kassahn, K. S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.09.060 · Cited by 209 · see citing works

Cystic precursors to invasive pancreatic cancer

Matthaei, H., Schulick, R. D., Hruban, R. H., & Maitra, A. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.2 · Cited by 193 · see citing works

Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes

Chmielecki, J., Hutchinson, K. E., Frampton, G. M., Chalmers, Z. R., Johnson, A., Shi, C., Elvin, J. A., Ali, S. M., Ross, J. S., Baştürk, O., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0617 · Cited by 188 · see citing works

Mutant TP53 in Duodenal Samples of Pancreatic Juice From Patients With Pancreatic Cancer or High-Grade Dysplasia

Kanda, M., Sadakari, Y., Borges, M., Topazian, M., Farrell, J., Syngal, S., Lee, J., Kamel, I., Lennon, A. M., Knight, S., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.11.016 · Cited by 181 · see citing works

Oncogenic <i>BRAF</i> Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120

Chen, S.-H., Zhang, Y., Van Horn, R. D., Yin, T., Buchanan, S., Yadav, V., Mochalkin, I., Wong, S. S., Yue, Y. G., Huber, L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0896 · Cited by 171 · see citing works

PIK3CA Mutations in Intraductal Papillary Mucinous Neoplasm/Carcinoma of the Pancreas

Schönleben, F., Qiu, W., Ciau, N. T., Ho, D. J., Li, X., Allendorf, J., Remotti, H. E., & Su, G. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0292 · Cited by 164 · see citing works

Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma

Singhi, A. D., Ali, S. M., Lacy, J., Hendifar, A. E., Nguyen, K., Koo, J., Chung, J., Greenbowe, J. R., Ross, J. S., Nikiforova, M. N., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0058 · Cited by 106 · see citing works

Targeted Therapies for Lung Cancer

Larsen, J. E., Cascone, T., Gerber, D. E., Heymach, J. V., & Minna, J. D. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823e701a · Cited by 103 · see citing works

Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?

Krantz, B. A., & O'Reilly, E. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3169 · Cited by 43 · see citing works

Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions.

Pishvaian, M. J., Rolfo, C. D., Liu, S. V., Multani, P. S., Maneval, E. C., & Garrido‐Laguna, I. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.521 · Cited by 38 · see citing works

Immediate referral to colposcopy versus cytological surveillance for low‐grade cervical cytological abnormalities in the absence of HPV test: A systematic review and a meta‐analysis of the literature

Kyrgiou, M., Kalliala, I. E. J., Mitra, A., Ng, K. Y. B., Raglan, O., Fotopoulou, C., Martin‐Hirsch, P. L., Paraskevaidis, E. A., & Arbyn, M. (2016) · International Journal of Cancer · doi:10.1002/ijc.30419 · Cited by 23 · see citing works

POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2mutation (gBRCAm) who have not progressed following first-line chemotherapy.

Kindler, H. L., Locker, G. Y., Mann, H., & Golan, T. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.tps4149 · Cited by 12 · see citing works

Overall survival of patients with pancreatic adenocarcinoma and BRCA1 or BRCA2 germline mutation.

Aung, K. L., Holter, S., Borgida, A., Connor, A. A., Pintilie, M., Dhani, N. C., Hedley, D. W., Knox, J. J., & Gallinger, S. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.4123 · Cited by 10 · see citing works

Pancreatic cancer: Advances and challenges

Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321 · see citing works

The Frequency of Ras Mutations in Cancer

Prior, I. A., Hood, F. E., & Hartley, J. L. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3682 · Cited by 1,130 · see citing works

Pancreatic cancer

Stoop, T. F., Javed, A. A., Oba, A., Koerkamp, B. G., Seufferlein, T. T. W., Wilmink, J. W., & Besselink, M. G. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00261-2 · Cited by 544 · see citing works

Therapeutic developments in pancreatic cancer

Hu, Z., & O'Reilly, E. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 425 · see citing works

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group

Mosele, M. F., Westphalen, C. B., Stenzinger, A., Barlési, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.005 · Cited by 443 · see citing works

Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers

Jiang, J., Jiang, L., Maldonato, B. J., Wang, Y., Holderfield, M., Aronchik, I., Winters, I. P., Salman, Z., Blaj, C., Menard, M., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0027 · Cited by 343 · see citing works

Molecular epidemiology and diagnostics of KRAS mutations in human cancer

Timar, J., & Kashofer, K. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09915-5 · Cited by 334 · see citing works

Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications

Luchini, C., Brosens, L. A. A., Wood, L. D., Chatterjee, D., Shin, J. I., Sciammarella, C., Fiadone, G., Malleo, G., Salvia, R., Kryklyva, V., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-320726 · Cited by 257 · see citing works

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications

Zhu, H., Wei, M., Xu, J., Hua, J., Chen, L., Meng, Q., Zhang, Y., Liu, J., Zhang, B., Yu, X., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01167-9 · Cited by 258 · see citing works

Translational advances in pancreatic ductal adenocarcinoma therapy

Hosein, A. N., Dougan, S. K., Aguirre, A. J., & Maitra, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00349-2 · Cited by 249 · see citing works

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

Melisi, D., Oh, D., Hollebecque, A., Calvo, E., Varghese, A. M., Borazanci, E. H., Macarulla, T. M., Merz, V., Zecchetto, C., Zhao, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002068 · Cited by 214 · see citing works

Prospective, Multi-Institutional, Real-Time Next-Generation Sequencing of Pancreatic Cyst Fluid Reveals Diverse Genomic Alterations That Improve the Clinical Management of Pancreatic Cysts

Paniccia, A., Polanco, P. M., Boone, B. A., Wald, A. I., McGrath, K., Brand, R. E., Khalid, A., Kubiliun, N. M., Lennon, A. M., Park, W. G., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.09.028 · Cited by 211 · see citing works

Autophagy as a therapeutic target in pancreatic cancer

Piffoux, M., Eriau, E., & Cassier, P. A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01039-5 · Cited by 182 · see citing works

Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures

Singhi, A. D., Nikiforova, M. N., Chennat, J. S., Papachristou, G. I., Khalid, A., Rabinovitz, M., Das, R. K., Sarkaria, S., Ayasso, M. S., Wald, A. I., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317817 · Cited by 177 · see citing works

Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas and Bile Duct

Singhi, A. D., Wood, L. D., Parks, E., Torbenson, M. S., Felsenstein, M., Hruban, R. H., Nikiforova, M. N., Wald, A. I., Kaya, C., Nikiforov, Y. E., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.10.028 · Cited by 167 · see citing works

Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis

Casolino, R., Paiella, S., Azzolina, D., Beer, P. A., Corbo, V., Lorenzoni, G., Gregori, D., Golan, T., Braconi, C., Froeling, F. E. M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03238 · Cited by 144 · see citing works

Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions

Lawlor, R. T., Mattiolo, P., Mafficini, A., Hong, S., Piredda, M. L., Taormina, S. V., Malleo, G., Marchegiani, G., Pea, A., Salvia, R., et al. (2021) · Cancers · doi:10.3390/cancers13133119 · Cited by 134 · see citing works

Pancreatic cancer in 2021: What you need to know to win

Tonini, V., & Zanni, M. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i35.5851 · Cited by 126 · see citing works

Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes

Federico, A. D., Mosca, M., Pagani, R., Carloni, R., Frega, G., Giglio, A. D., Rizzo, A., Ricci, D., Tavolari, S., Marco, M. D., et al. (2022) · Cancers · doi:10.3390/cancers14102429 · Cited by 115 · see citing works

BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects

Wong, W., Raufi, A. G., Safyan, R. A., Bates, S. E., & Manji, G. A. (2020) · Cancer Management and Research · doi:10.2147/cmar.s211151 · Cited by 109 · see citing works

Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures

Arechederra, M., Rullán, M., Amat, I., Oyón, D., Zabalza, L., Elizalde, M., Latasa, M. U., Mercado, M., Ruiz-Clavijo, D., Saldaña, C., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-325178 · Cited by 109 · see citing works

Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program

Pishvaian, M. J., Blais, E. M., Brody, J. R., Rahib, L., Lyons, E. E., Arbeloa, P., Hendifar, A. E., Mikhail, S., Chung, V. M., Sohal, D. P. S., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00115 · Cited by 103 · see citing works

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities

Luchini, C., Paolino, G., Mattiolo, P., Piredda, M. L., Cavaliere, A., Gaule, M., Melisi, D., Salvia, R., Malleo, G., Shin, J. I., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01732-6 · Cited by 101 · see citing works

Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

Overman, M. J., Javle, M. M., Davis, R. E., Vats, P., Kumar‐Sinha, C., Xiao, L., Mettu, N. B., Parra, E. R., Benson, A. B., Lopez, C. D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000587 · Cited by 94 · see citing works

A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)

Ozaka, M., Nakachi, K., Kobayashi, S., Ohba, A., Imaoka, H., Terashima, T., Ishii, H., Mizusawa, J., Katayama, H. G., Kataoka, T., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.12.014 · Cited by 94 · see citing works

Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications

Martens, S., Lefesvre, P., Nicolle, R., Biankin, A. V., Puleo, F., Laethem, J. V., & Rooman, I. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz181 · Cited by 78 · see citing works

The Desmoplastic Stroma of Pancreatic Cancer: Multilayered Levels of Heterogeneity, Clinical Significance, and Therapeutic Opportunities

Masugi, Y. (2022) · Cancers · doi:10.3390/cancers14133293 · Cited by 81 · see citing works

The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma

Rhee, H., & Park, M.-S. (2020) · Korean Journal of Radiology · doi:10.3348/kjr.2019.0862 · Cited by 64 · see citing works

The tumor therapy landscape of synthetic lethality

Zhang, B., Tang, C., Yao, Y., Chen, X., Zhou, C., Wei, Z., Xing, F., Chen, L., Cai, X., Zhang, Z., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21544-2 · Cited by 72 · see citing works

Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma

Grant, R. C., Denroche, R. E., Jang, G. H., Nowak, K. M., Zhang, A. X. W., Borgida, A., Holter, S., Topham, J. T., Wilson, J. M., Dodd, A., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-320730 · Cited by 71 · see citing works

The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer

Kimura, H., Klein, A. P., Hruban, R. H., & Roberts, N. J. (2021) · Pancreas · doi:10.1097/mpa.0000000000001888 · Cited by 65 · see citing works

Immunotherapy in Pancreatic Adenocarcinoma: Beyond “Copy/Paste”

Hester, R., Mazur, P. K., & McAllister, F. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0900 · Cited by 65 · see citing works

A Combined DNA/RNA-based Next-Generation Sequencing Platform to Improve the Classification of Pancreatic Cysts and Early Detection of Pancreatic Cancer Arising From Pancreatic Cysts

Nikiforova, M. N., Wald, A. I., Spagnolo, D. M., Melan, M. A., Grupillo, M., Lai, Y.-T., Brand, R. E., Lennon, A. M., McGrath, K., Park, W. G., et al. (2023) · Annals of Surgery · doi:10.1097/sla.0000000000005904 · Cited by 66 · see citing works

Improving outcomes of patients with pancreatic cancer

Dreyer, S. B., Beer, P. A., Hingorani, S. R., & Biankin, A. V. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01019-9 · Cited by 66 · see citing works

Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer

Zhang, X., Mao, T., Zhang, B., Xu, H., Cui, J., Jiao, F., Chen, D., Wang, Y., Hu, J., Xia, Q., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103897 · Cited by 62 · see citing works

KRAS G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation?

Shen, H., Lundy, J., Strickland, A. H., Harris, M., Swan, M. P., Desmond, C., Jenkins, B. J., & Croagh, D. G. (2022) · Cells · doi:10.3390/cells11193175 · Cited by 57 · see citing works

Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature

Gupta, M., Sherrow, C., Krone, M. E., Blais, E. M., Pishvaian, M. J., Petricoin, E. F., Matrisian, L. M., DeArbeloa, P., Gregory, G., Brown, A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7641 · Cited by 53 · see citing works

Molecular Subtyping and Precision Medicine for Pancreatic Cancer

Froeling, F. E. M., Casolino, R., Pea, A., Biankin, A. V., Chang, D. K.-F., & Precision-Panc, O. B. O. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10010149 · Cited by 50 · see citing works

Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers

Taherian, M., Wang, H., & Wang, H. (2022) · Cells · doi:10.3390/cells11193068 · Cited by 49 · see citing works

Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer

Singh, H., Keller, R. B., Kapner, K. S., Dilly, J., Raghavan, S., Yuan, C., Cohen, E. F., Tolstorukov, M. Y., Andrews, E., Brais, L. K., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3930 · Cited by 46 · see citing works

Next-generation therapies for pancreatic cancer

Buckley, C. W., & O'Reilly, E. M. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2322648 · Cited by 47 · see citing works

Multi‐omics analysis of intra‐tumoural and inter‐tumoural heterogeneity in pancreatic ductal adenocarcinoma

Liu, X., Wang, W., Liu, X., Zhang, Z., Yu, L., Li, R., Guo, D., Cai, W., Quan, X., Wu, H., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.670 · Cited by 43 · see citing works

Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies

Rozengurt, E., & Eibl, G. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02499-y · Cited by 45 · see citing works

Targeting DNA damage repair pathways in pancreas cancer

Crowley, F., Park, W., & O’Reilly, E. M. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09983-1 · Cited by 43 · see citing works

Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives

Adamopoulos, C., Cave, D. D., & Papavassiliou, A. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031631 · Cited by 41 · see citing works

RET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas

Chou, A. S. Y., Brown, I., Kumarasinghe, P. M., Perren, A. A., Riley, D., Kim, Y., Pajic, M., Steinmann, A. M., Rathi, V., Jamieson, N. B., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0373-y · Cited by 40 · see citing works

Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies

Turpin, A., Neuzillet, C., Colle, E., Dusetti, N., Nicolle, R., Cros, J. F., de Mestier, L., Bachet, J., & Hammel, P. R. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221118019 · Cited by 39 · see citing works

The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go

Thompson, E. D., Roberts, N. J., Wood, L. D., Eshleman, J. R., Goggins, M., Kern, S. E., Klein, A. P., & Hruban, R. H. (2020) · Modern Pathology · doi:10.1038/s41379-020-0629-6 · Cited by 39 · see citing works

Evolving pancreatic cancer treatment: From diagnosis to healthcare management

Milella, M., Bassi, C., Boggi, U., Brunetti, O., Cavaliere, A., Crippa, S., Vita, F. D., Falconi, M., Frassineti, G. L., Giommoni, E., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103571 · Cited by 37 · see citing works

Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians

Giannis, D., Moris, D., & Barbas, A. S. (2021) · Cancers · doi:10.3390/cancers13051071 · Cited by 37 · see citing works

Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity

Fu, Z., Chen, S., Zhu, Y., Zhang, D., Xie, P., Jiao, Q., Chi, J. J., Xu, S., Xue, Y., Lu, X., et al. (2023) · Science Advances · doi:10.1126/sciadv.add6626 · Cited by 37 · see citing works

Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities

Chakrabarti, S., Kamgar, M., & Mahipal, A. (2022) · Cancers · doi:10.3390/cancers14112588 · Cited by 36 · see citing works

Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals a Link between Glucose Metabolism and PD-1+ Cells

Cortese, N., Capretti, G. L., Barbagallo, M., Rigamonti, A., Takis, P. G., Castino, G. F., Vignali, D., Maggi, G., Gavazzi, F., Ridolfi, C., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0403 · Cited by 35 · see citing works

Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma

George, B., Kudryashova, O. M., Kravets, A. D., Thalji, S. Z., Malarkannan, S., Kurzrock, R., Chernyavskaya, E. F., Gusakova, M., Kravchenko, D., Tychinin, D. I., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.028 · Cited by 35 · see citing works

Fusion genes in pancreatic tumors

Γκουντάκος, Α., Singhi, A. D., Westphalen, C. B., Scarpa, A., & Luchini, C. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.01.009 · Cited by 34 · see citing works

Moving the Needle on Precision Medicine in Pancreatic Cancer

O'Kane, G. M., & Lowery, M. A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02514 · Cited by 34 · see citing works

Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II trial

Cheng, K., Li, X., Lv, W., Zhao, G., Zhou, R., Chen, C., Yang, H., Li, R., Li, Z., Chen, Y., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02031-8 · Cited by 33 · see citing works

From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer

Bazzichetto, C., Conciatori, F., Luchini, C., Simionato, F., Santoro, R., Vaccaro, V., Corbo, V., Falcone, I., Ferretti, G., Cognetti, F., et al. (2020) · Cells · doi:10.3390/cells9020309 · Cited by 33 · see citing works

Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine inKRASWild-Type Pancreatic Cancer

Fusco, M. J., Saeed‐Vafa, D., Carballido, E. M., Boyle, T. A., Malafa, M. P., Blue, K., Teer, J. K., Walko, C. M., McLeod, H. L., Hicks, J. K., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00265 · Cited by 34 · see citing works

ALK Inhibitors in Patients With ALK Fusion–Positive GI Cancers: An International Data Set and a Molecular Case Series

Ambrosini, M., Re, M. D., Manca, P., Hendifar, A. E., Drilon, A. E. D. C., Harada, G., Ree, A. H., Klempner, S. J., Mælandsmo, G. M., Flatmark, K., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00015 · Cited by 33 · see citing works

Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer

Umemoto, K., Sunakawa, Y., Ueno, M., Furukawa, M., Mizuno, N., Sudo, K., Kawamoto, Y., Kajiwara, T., Ohtsubo, K., Okano, N., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02189-y · Cited by 34 · see citing works

Malignant epithelial/exocrine tumors of the pancreas

Luchini, C., Grillo, F., Fassan, M., Vanoli, A., Capelli, P., Paolino, G., Ingravallo, G., Renzulli, G., Doglioni, C., D’Amuri, A., et al. (2020) · Pathologica · doi:10.32074/1591-951x-167 · Cited by 32 · see citing works

Precision medicine for KRAS wild-type pancreatic adenocarcinomas

Ben-Ammar, I., Rousseau, A., Nicolle, R., Tarabay, A., Boige, V., Valéry, M., Pudlarz, T., Malka, D., Gelli, M., Fernandez-De-Sevilla, E., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113497 · Cited by 31 · see citing works

Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance

Rozengurt, E., & Eibl, G. (2021) · Cancers · doi:10.3390/cancers13205126 · Cited by 30 · see citing works

ATM Serine/Threonine Kinase and its Role in Pancreatic Risk

Nanda, N., & Roberts, N. J. (2020) · Genes · doi:10.3390/genes11010108 · Cited by 29 · see citing works

Efficacy of EUS-guided FNB using a Franseen needle for tissue acquisition and microsatellite instability evaluation in unresectable pancreatic lesions

Sugimoto, M., Irie, H., Takagi, T. J., Suzuki, R., Konno, N., Asama, H., Sato, Y., Nakamura, J., Takasumi, M., Hashimoto, M., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07588-5 · Cited by 29 · see citing works

Biomarkers for early detection of pancreatic cancer – miRNAs as a potential diagnostic and therapeutic tool?

Tarasiuk, A., Mackiewicz, T., Malecka-Panas, E. I., & Fichna, J. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.1941584 · Cited by 29 · see citing works

Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies

Hendifar, A. E., Blais, E. M., Wolpin, B. M., Subbiah, V., Collisson, E. A., Singh, I., Cannon, T. L., Shaw, K. R. M., Petricoin, E. F., Klempner, S. J., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00494 · Cited by 31 · see citing works

The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling

Umemoto, K., Yamamoto, H., Oikawa, R., Takeda, H., Doi, A., Horie, Y., Arai, H., Ogura, T., Mizukami, T., Izawa, N., et al. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac106 · Cited by 29 · see citing works

Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma

Huffman, B. M., Ellis, H., Jordan, A. C., Freed-Pastor, W. A., Perez, K. J., Rubinson, D. A., Sethi, N. S., Singh, H., Surana, R., Wolpin, B. M., et al. (2022) · Cancers · doi:10.3390/cancers14246223 · Cited by 30 · see citing works

Clinical and genomic characterisation of early-onset pancreatic cancer

Castet, F., Fabregat-Franco, C., Castillo, G., Navarro, V., Sierra, A., Acosta, D. A., López-Valbuena, D., Dienstmann, R., Tabernero, J. M., Vivancos, A. P., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113338 · Cited by 29 · see citing works

The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment

Sun, H., Zhang, B., & Li, H. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820920969 · Cited by 28 · see citing works

Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities

Lee, M. S., & Pant, S. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321255 · Cited by 29 · see citing works

Targeting KRAS in Pancreatic Cancer

Cowzer, D., Zameer, M., Conroy, M. R., Kölch, W., & Duffy, A. G. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111870 · Cited by 29 · see citing works

Oncogenic KRAS-Induced Feedback Inflammatory Signaling in Pancreatic Cancer: An Overview and New Therapeutic Opportunities

Bansod, S., Dodhiawala, P. B., & Lim, K. (2021) · Cancers · doi:10.3390/cancers13215481 · Cited by 26 · see citing works

Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?

Rémond, M., Pellat, A., Brézault, C., Dhooge, M., & Coriat, R. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100638 · Cited by 27 · see citing works

Immunosuppressive tumor microenvironment in pancreatic cancer: mechanisms and therapeutic targets

Pan, D., Li, X., Qiao, X., & Wang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1582305 · Cited by 26 · see citing works

Targeting DNA Damage Repair Mechanisms in Pancreas Cancer

Perkhofer, L., Golan, T., Cuyle, P.-J. A., Matysiak‐Budnik, T., Laethem, J. V., Macarulla, T. M., Cauchin, E., Kleger, A., Beutel, A. K., Gout, J., et al. (2021) · Cancers · doi:10.3390/cancers13174259 · Cited by 25 · see citing works

Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort

Zhan, Q., Wen, C., Zhao, Y., Fang, L., Jin, Y., Zhang, Z., Zou, S., Li, F., Yang, Y., Wu, L., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103716 · Cited by 25 · see citing works

BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features, and Therapeutic Opportunities

Ciner, A., Jiang, Y., & Hausner, P. F. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0626 · Cited by 25 · see citing works

Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples

Semaan, A., Bernard, V., Lee, J. J., Wong, J., Huang, J. H., Swartzlander, D. B., Stephens, B. M., Monberg, M. E., Weston, B. R., Bhutani, M. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2667 · Cited by 24 · see citing works

Animal Models of Cancer-Related Pain: Current Perspectives in Translation

Pineda-Farías, J. B., Saloman, J. L., & Scheff, N. N. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.610894 · Cited by 24 · see citing works

Roles of the nervous system in pancreatic cancer

Wakiya, T., Ishido, K., Yoshizawa, T., Kanda, T., & Hakamada, K. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12459 · Cited by 22 · see citing works

Age and prognosis in patients with pancreatic cancer: a population-based study

van Dongen, J. C., van der Geest, L. G., de Meijer, V. E., van Santvoort, H. C., de Vos‐Geelen, J., Besselink, M. G., Koerkamp, B. G., Wilmink, J. W., van Eijck, C. H. J., & on behalf of the Dutch Pancreatic Cancer Group (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.2016949 · Cited by 24 · see citing works

KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer

Dai, M., Chen, S., Teng, X., Chen, K., & Cheng, W. (2022) · Journal of Cancer · doi:10.7150/jca.76695 · Cited by 24 · see citing works

Ca2+ Signaling and Its Potential Targeting in Pancreatic Ductal Carcinoma

Bettaieb, L., Brulé, M., Chomy, A., Diedro, M., Fruit, M., Happernegg, E., Heni, L., Horochowska, A., Housseini, M., Klouyovo, K., et al. (2021) · Cancers · doi:10.3390/cancers13123085 · Cited by 24 · see citing works

Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance

Kimura, H., Paranal, R. M., Nanda, N., Wood, L. D., Eshleman, J. R., Hruban, R. H., Goggins, M. G., Klein, A. P., The Familial Pancreatic Cancer Genome Sequencing Project, & Roberts, N. J. (2022) · eLife · doi:10.7554/elife.71137 · Cited by 23 · see citing works

Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Ng, C., Glaspy, J. A., Placencio-Hickok, V., Thomassian, S., Gong, J., Osipov, A., Hendifar, A. E., & Moshayedi, N. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7039 · Cited by 23 · see citing works

Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment

Crowley, F., Gandhi, S., Rudshteyn, M., Sehmbhi, M., & Cohen, D. J. (2023) · The Oncologist · doi:10.1093/oncolo/oyad044 · Cited by 23 · see citing works

Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database

Sakakida, T., Ishikawa, T., Doi, T., Morita, R., Kataoka, S., Miyake, H., Yamaguchi, K., Moriguchi, M., Sogame, Y., Yasuda, H., et al. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-02058-8 · Cited by 23 · see citing works

Resection of Recurrent Pancreatic Cancer: Who Can Benefit?

Nienhüser, H., Büchler, M. W., & Schneider, M. A. (2021) · Visceral Medicine · doi:10.1159/000519754 · Cited by 22 · see citing works

Endoscopic ultrasound‐guided tissue acquisition for pancreatic ductal adenocarcinoma in the era of precision medicine

Ashida, R., & Kitano, M. (2022) · Digestive Endoscopy · doi:10.1111/den.14344 · Cited by 22 · see citing works

Endoscopic ultrasound may be used to deliver gene expression signatures using digital mRNA detection methods to immunophenotype pancreatic ductal adenocarcinoma to facilitate personalized immunotherapy

Gleeson, F. C., Levy, M. J., Jackson, R. A., Murphy, S. J., Halling, K. C., Kipp, B. R., Graham, R. P., & Zhang, L. (2019) · Pancreatology · doi:10.1016/j.pan.2019.12.002 · Cited by 21 · see citing works

Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification

Nasca, V., Chiaravalli, M., Piro, G., Esposito, A., Salvatore, L., Tortora, G., Corbo, V., & Carbone, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176386 · Cited by 21 · see citing works

Poly( ADP ‐ribose) polymerase inhibition in pancreatic cancer

Singh, H. M., Bailey, P. J., Hübschmann, D., Berger, A. K., Neoptolemos, J. P., Jäger, D., Siveke, J. T., & Springfeld, C. (2020) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22932 · Cited by 21 · see citing works

First international workshop of the ATM and cancer risk group (4-5 December 2019)

Lesueur, F., Easton, D. F., Renault, A., Tavtigian, S. V., Bernstein, J. L., Kote‐Jarai, Z., Eeles, R. A., Plaseska-Karanfia, D., Feliubadaló, L., Spanish ATM working group, et al. (2021) · Familial Cancer · doi:10.1007/s10689-021-00248-y · Cited by 21 · see citing works

Immunotherapy and Pancreatic Cancer: A Lost Challenge?

Laface, C., Memeo, R., Maselli, F. M., Santoro, A. N., Iaia, M. L., Ambrogio, F., Laterza, M., Cazzato, G., Guarini, C., Santis, P. D., et al. (2023) · Life · doi:10.3390/life13071482 · Cited by 21 · see citing works

Novel ALK Fusion, PPFIBP1-ALK , in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib

Gower, A., Golestany, B., Gong, J., Singhi, A. D., & Hendifar, A. E. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00365 · Cited by 23 · see citing works

Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC

Digiacomo, G., Volta, F., Garajová, I., Balsano, R., & Cavazzoni, A. (2021) · Life · doi:10.3390/life11080843 · Cited by 20 · see citing works

Advancements in Systemic Therapy for Pancreatic Cancer

Brown, T. J., Reiss, K. A., & O’Hara, M. H. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_397082 · Cited by 20 · see citing works

Current and emerging trends in the treatment of metastatic colorectal cancer

Glover, K. Y., & Eng, C. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(07)80005-0

Comprehensive genomic profiling (CGP) in KRAS wild-type (WT) pancreatic ductal adenocarcinoma (PDAC).

George, B., Greenbowe, J. R., Hendifar, A. E., Golan, T., Javle, M. M., Maitra, A., Bahary, N., Schrock, A. B., Stephens, P. J., Miller, V. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.271

1543P Clinical relevance of somatic and germline alterations in patients with pancreatic ductal adenocarcinoma

Wang, F., Liu, Q., Li, X., Yuan, H., Ma, T., Liu, R., Zhao, Z., & Zhang, X.-Y. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2026

Genomic profiling of KRAS wide-type pancreatic ductal adenocarcinomas identifies targetable genetic alterations.

Deng, W., Li, X., Zhang, X., Ma, T., & Liu, R. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.4121 · Cited by 1 · see citing works

AB095. P069. Identification of therapeutic genomic alterations by investigating cancer-related genes and microsatellite instability: road to precision medicine for pancreatic ductal adenocarcinoma

Program, O. B. O. J. H. P. M., Ding, D., Javed, A. A., Cunningham, D., Teinor, J. A., Wright, M. J., Yuan, C., Wilt, C., Ryan, A., Judkins, C., et al. (2018) · Annals of Pancreatic Cancer · doi:10.21037/apc.2018.ab095